심낭염 시장 : 규모, 점유율, 성장 분석, 약제별, 투여 경로별, 최종 사용자별, 유통 채널별, 지역별, 업계 예측(2025-2032년)

Global Pericarditis Market size was valued at USD 3.8 billion in 2023 and is poised to grow from USD 4.05 billion in 2024 to USD 6.81 billion by 2032, growing at a CAGR of 6.7% during the forecast period (2025-2032).

The global pericarditis market is witnessing steady expansion driven by the rising prevalence of pericardial diseases and enhanced awareness among healthcare professionals. Innovations in diagnostic technologies are facilitating better detection and management of these conditions. Furthermore, the increasing adoption of targeted and transcatheter therapies, along with improved healthcare access in developing regions, is fostering a larger patient demographic. Additionally, advancements in clinical guidelines are promoting earlier intervention and treatment strategies, which collectively support market growth and improve patient outcomes. This confluence of factors positions the pericarditis market for continued development and increased investment opportunities in the healthcare sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pericarditis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pericarditis Market Segments Analysis

Global Pericarditis Market is segmented by Drugs, Route of Administration, End User, Distribution Channel and region. Based on Drugs, the market is segmented into Nonsteroidal Anti-Inflammatory Agents (NSAIDs), Steroids, Antibiotics, Colchicine and Others. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pericarditis Market

The expanding prevalence of inflammatory cardiovascular conditions, particularly pericarditis, is significantly propelling the growth of the market. This rise in patient numbers can be linked to various factors, including shifts in lifestyle, an increase in autoimmune diseases, and the aftermath of viral infections, all contributing to a higher incidence of these conditions. As the patient population with inflammatory cardiovascular diseases continues to grow, there is an increasing demand for improved diagnostic methods, precise treatment options, and continuous monitoring and management strategies. These needs are prompting innovations within health systems to enhance patient care and outcomes in the management of pericarditis.

Restraints in the Global Pericarditis Market

The Global Pericarditis market faces significant challenges due to the frequent occurrence of undiagnosed or misdiagnosed cases, especially in primary care settings and areas with limited resources. The absence of prominent symptoms, combined with insufficient awareness among general practitioners and the lack of standardized screening protocols, hinders timely diagnosis and treatment. This situation often results in delayed care, which not only impacts patient outcomes but also restricts the overall market potential, particularly in developing countries where healthcare infrastructure may be lacking. Addressing these barriers is essential for enhancing diagnosis rates and expanding market opportunities.

Market Trends of the Global Pericarditis Market

The global pericarditis market is witnessing a notable shift towards biologic therapies, reflecting an increased demand for advanced treatment options, particularly among patients with recurrent pericarditis who do not respond adequately to conventional anti-inflammatory medications. Biologic agents, such as IL-1 inhibitors, are gaining traction for their efficacy in providing improved long-term outcomes, lower recurrence rates, and enhanced tolerability. This trend is particularly pronounced in developed healthcare systems, where there is a growing emphasis on personalized medicine and innovative therapies, indicating a potential shift in clinical practice and treatment paradigms within the pericarditis management landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Pericarditis Market Size by Drugs & CAGR (2025-2032)

• Market Overview
• Nonsteroidal Anti-Inflammatory Agents (NSAIDs)
• Steroids
• Antibiotics
• Colchicine
• Others

Global Pericarditis Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Others

Global Pericarditis Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Pericarditis Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Pericarditis Market Size & CAGR (2025-2032)

• North America (Drugs, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Drugs, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drugs, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drugs, Route of Administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drugs, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Kiniksa Pharmaceuticals, Ltd. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardiol Therapeutics (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Co. Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals USA, Inc. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cumberland Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Scilex Holding Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Par Pharmaceutical (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Azure Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Midas Pharma GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations